Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04711187 | Study of AT-527 in Healthy Subjects (R07496998) | PHASE1 | COMPLETED | 81 | — | — | Nov 2, 2020 | Sep 15, 2021 | Feb 25, 2022 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| AT-527 Formulation 1 Dose 1 | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 1 | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 2 | EXPERIMENTAL | - |
| AT-527 Formulation 1 Dose 3 | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 3 | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 1 Fast/Fed | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 3 Fast/Fed | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AT-527 Formulation 1 | DRUG | AT-527 Formulation 1 (R07496998) |
| Placebo Comparator | OTHER | Placebo Comparator |
| AT-527 Formulation 2 | DRUG | AT-527 Formulation 2 (R07496998) |
Inclusion Criteria: * Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug * Females must have a negative pregnancy test at Screening and prior to dosing * Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg...